AbbVie receives EC approval for Aquipta to treat migraine
Pharmaceutical Technology
AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.
pharminent
June 3, 2026 (Last updated: June 3, 2026)
Pharmaceutical Technology
AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.